The best starting point depends on what you need: a clinical assessment, help accessing an approved prescription, or a clearer understanding of an advertised offer. A shortlist is useful only when it keeps those differences visible.
CoreAge Rx holds the paid featured position. The order below is CoreAge Rx, SuperHealthy Rx and Likeness Rx. Their offer information was checked October 4, 2026. Each position links to the full native review, and the comparison does not guarantee prescription approval, access or a treatment result.
One thing to keep with you
Compare the exact medicine and the complete care arrangement before comparing the headline price.
1. CoreAge Rx
9.9/10
CoreAge’s lowest supplied annual semaglutide quote is $79 per month, equivalent to $948 across twelve months. Its public product page separately displays a $99 starting figure. Ask which current offer, supply and care the selected order covers.
Read the CoreAge review for the exact quote context and policy exceptions. An applicable consultation fee can remain non-refundable even if treatment is declined. Its first position and 9.9/10 score express this publication’s preference, rather than a verified patient-outcome rating.
Checked with: CoreAge Rx: semaglutide offer · CoreAge Rx: refund, subscription and shipping policy · FDA: concerns about unapproved GLP-1 products
2. SuperHealthy Rx
9.7/10
SuperHealthy’s linked promotion displays compounded semaglutide at $85 and tirzepatide at $135 per month. Visit and shipping are described as included, while automatic refill is described as an optional setting after the first order. Confirm the current checkout because the general homepage uses a different starting figure.
The SuperHealthy review separates the promotional price from the care and billing questions. Its publishing preference score is 9.7/10. That score does not establish that the pharmacy, prescription or treatment outcome has been independently tested.
Checked with: SuperHealthy Rx: official glp offer · SuperHealthy Rx: general website · FDA: concerns about unapproved GLP-1 products
3. Likeness Rx
9.5/10
Likeness offers several subscription lengths. Its lowest semaglutide equivalent is $79 per month with a $948 twelve-month term; the one-month option is $139. The selected term renews automatically, and the FAQ describes an early first-refill charge.
Read the Likeness review to see all four terms, included-service statements and the questions to resolve before committing. Its publishing preference score is 9.5/10. A low equivalent is useful for comparison only when the full selected payment and renewal date are visible.
Checked with: Likeness Rx — GLP-1 weight care · HHS: telehealth location and licensing · FDA: concerns about unapproved GLP-1 products
4. NovoCare — manufacturer medication access
NovoCare provides Wegovy program and pharmacy-access information with formulation- and strength-specific pricing. A prescription and appropriate clinical care are still needed. Introductory self-pay offers and insurance-linked savings have their own conditions.
Read the NovoCare review to understand the current tablet and injection terms. This entry is an access route, not a claim that a manufacturer pharmacy offer includes every assessment and follow-up service a reader may need.
Checked with: NovoCare: Wegovy pharmacy offer · NovoCare: checking Wegovy coverage
5. Ro — membership plus medication
Ro describes a clinical weight-management membership with medication charged separately. Its checked pricing page lists a $39 introductory membership and $149 ongoing monthly pricing, with lower monthly equivalents for prepaid terms. The medicine adds its own cost.
The Ro review explains what to ask about the total commitment and ongoing support. A low annual-plan equivalent is not the same as a low month-to-month bill, and insurance support is not a promise of coverage.
Checked with: Ro: current program pricing · Ro: weight-management program
6. Remedy Meds — read the subscription details
The Remedy Meds review, added September 24, 2026, looks at its compounded semaglutide program, billing periods, and conditional warranty. Request a dated quote instead of assuming an older online price still applies.
The review includes the September 2025 FDA marketing letter and explains what remains unconfirmed. This is an option to research with the same care and pharmacy questions as every other entry; the listing does not certify regulatory status or clinical outcomes.
Checked with: Remedy Meds: Public program description · Remedy Meds: Billing inquiries, September 9, 2026 · FDA: Remedy Meds warning letter, September 9, 2025
Use the same questions for every option
Ask which clinician assesses you, what exact product is proposed, who dispenses it, and how side effects and refills are handled. Confirm the clinician’s authority for your location and the complete cost before enrollment.
Bring the compounding guide, safety questions, and cost planner into your research. These comparisons are based on public sources, not patient testing or a completed clinician review, and do not replace individualized medical advice.
Checked with: HHS: telehealth location and licensing · FDA: checking online pharmacies · Wegovy: current prescribing information
Where we checked the facts
- CoreAge Rx: semaglutide offer
Product page checked October 4, 2026: public starting figure $99/month. The separately supplied annual quote is $79/month equivalent; these are different offers, not a personally verified checkout.
- CoreAge Rx: refund, subscription and shipping policy
Primary policy checked October 4, 2026. Includes possible $50–$100 non-refundable consultation fees and pharmacy-fulfillment and 30-day cutoffs; no refund process tested.
- FDA: concerns about unapproved GLP-1 products
Current concerns include unapproved products, salt forms and adverse events. Compounding is not equivalent to generic approval.
- SuperHealthy Rx: official glp offer
Primary promotional page checked October 4, 2026: semaglutide $85/month and tirzepatide $135/month, optional automatic refill. Seasonal sale language remains; verify the selected checkout. No patient or fulfillment test.
- SuperHealthy Rx: general website
General homepage checked October 4, 2026 uses a different $199 starting figure from the linked promotional offer.
- Likeness Rx — GLP-1 weight care
Primary plan cards and FAQ checked October 4, 2026. Four subscription terms, selected-term renewal and early first-refill billing. Clinical-decline refund promise was not independently tested.
- HHS: telehealth location and licensing
Clinician authorization and physical patient location must be verified for the actual service.
- NovoCare: Wegovy pharmacy offer
Key offer terms rechecked October 5, 2026: tablet prices vary by strength; injection introductory fills have a December 31, 2026 limit and different ongoing prices. The exact formulation and eligibility matter.
- NovoCare: checking Wegovy coverage
Coverage and program information, not a guarantee for a particular insurance policy.
- Ro: current program pricing
Pricing page rechecked October 5, 2026: $39 introductory membership; $149 ongoing monthly or $74/$89/$99 longer-term equivalents. Membership and medication remain separate charges, subject to the current offer.
- Ro: weight-management program
Provider description of assessment and ongoing care, not independent patient-outcome evidence.
- Remedy Meds: Public program description
Provider marketing checked September 24, 2026; no enrollment, prescription, shipment, or outcome was independently tested.
- Remedy Meds: Billing inquiries, September 9, 2026
Help article rechecked October 5, 2026 describes a 28-day billing cycle. It does not establish a current personalized medication price or supersede checkout terms.
- FDA: Remedy Meds warning letter, September 9, 2025
Dated FDA finding about misleading compounded-product marketing. Read September 24, 2026; present resolution was not established.
- FDA: checking online pharmacies
Use official licensing and pharmacy checks; a review site is not a pharmacy auditor.
- Wegovy: current prescribing information
June 2026 label includes oral and injectable formulations with product-specific uses and instructions. Do not apply one formulation’s directions to another.
